Kahn Brothers Group Inc. Purchases New Stake in Haleon PLC Sponsored ADR $HLN

Kahn Brothers Group Inc. purchased a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) during the second quarter, HoldingsChannel reports. The institutional investor purchased 58,341 shares of the company’s stock, valued at approximately $544,000.

Several other institutional investors also recently bought and sold shares of HLN. IHT Wealth Management LLC increased its position in shares of Haleon by 6.9% in the fourth quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock worth $164,000 after acquiring an additional 1,049 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of Haleon by 6.7% during the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock valued at $156,000 after acquiring an additional 1,099 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Haleon by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock valued at $250,000 after acquiring an additional 1,100 shares in the last quarter. Cary Street Partners Financial LLC boosted its position in Haleon by 20.1% during the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after purchasing an additional 1,113 shares during the period. Finally, Advisory Services Network LLC increased its holdings in Haleon by 7.1% in the 3rd quarter. Advisory Services Network LLC now owns 17,431 shares of the company’s stock valued at $156,000 after purchasing an additional 1,155 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Price Performance

HLN opened at $10.04 on Friday. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The firm has a market cap of $44.24 billion, a price-to-earnings ratio of 25.76, a PEG ratio of 2.03 and a beta of 0.12. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The company has a fifty day simple moving average of $9.77 and a 200 day simple moving average of $9.80.

Haleon Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.0642 per share. The ex-dividend date is Friday, August 14th. This represents a dividend yield of 132.0%. Haleon’s dividend payout ratio (DPR) is currently 30.77%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Zacks Research raised Haleon from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.